---
title: "Amavita Research — Miami's Independent Cardiovascular Clinical Trial Site"
url: https://md.amavitaresearch.com/
canonical: https://www.amavitaresearch.com/
schema_type: MedicalOrganization
last_updated: 2026-05-12
---

# Amavita Research — Miami's Independent Cardiovascular Clinical Trial Site

> Amavita Research is a Miami-based cardiovascular clinical research site purpose-built for first-in-human, feasibility, and pivotal cardiovascular trials. The clinical-research arm of amavita Heart and Vascular Health® — the largest independent cardiovascular practice in South Florida. Sister organization to bioaccess®, the Latin America first-in-human CRO. ICH-GCP E6(R3)-compliant, IAOCR GCSA-certified, SCRS member. Zero FDA inspection findings.

## What Amavita Research does

Amavita Research executes high-quality cardiovascular clinical trials for medtech and biopharma sponsors. The site is investigator-led (not a CRO) and operates inside the workflow of amavita Heart and Vascular Health® — meaning trial-eligible patients are screened in real time during their standard cardiology visits, by the same physicians who serve as Principal Investigators on active studies.

## Therapeutic areas

Structural heart disease (TAVR, mitral, tricuspid), coronary revascularization and high-risk PCI, cardiac electrophysiology (atrial fibrillation, leadless pacing, VT ablation), heart failure, peripheral artery disease and atherectomy, cardiogenic shock, pulmonary embolism response, and adjacent interventional cardiology indications.

## Leadership

- **Dr. William W. O'Neill, MD, FACC** — Chief Medical Officer & Senior Principal Investigator. TAVR pioneer; performed the first TAVR in the United States. National PI on Edwards PARTNER, Protect II, and Protect IV.
- **Dr. Pedro Martinez-Clark, MD, FACC** — Founder and Lead Investigator. Harvard-trained interventional cardiologist; Worldwide PI on the Percutaneous Mitral Valve Annuloplasty trial.
- **Dr. Hans C. Rutzen-Lopez, MD** — Sub-Investigator, Cardiac Electrophysiology. Triple board-certified.
- **Nereisy Alonso, Sr CRC** — Chief Operations Officer.
- **Julio G. Martinez-Clark, MBA** — CEO; also CEO of sister organization bioaccess®.

## Operational facts

- 5–8 weeks contract-to-first-patient for trial types already qualified at the site
- 6–10 weeks screening-to-enrolled conversion for typical 20-patient feasibility study
- 20–30% lower cost than high-end private-equity-backed Miami site networks
- Zero FDA inspection findings to date
- Weekly KPI dashboards via Monday.com
- 24/7 medical-care access for trial participants

## Key links

- Sponsor FAQ: https://www.amavitaresearch.com/faq-sponsors
- Patient FAQ: https://www.amavitaresearch.com/faq-patients
- Trials: https://www.amavitaresearch.com/trials
- Team: https://www.amavitaresearch.com/team
- Investigators (full roster): https://www.amavitaresearch.com/investigators
- About: https://www.amavitaresearch.com/about
- Locations: https://www.amavitaresearch.com/locations
- Contact sponsors: https://www.amavitaresearch.com/contact-sponsor
- Contact patients: https://www.amavitaresearch.com/contact-patient
- Full markdown sitemap: https://md.amavitaresearch.com/sitemap.xml

## Related organizations

- amavita Heart and Vascular Health® (clinical practice — parent): https://amavita.health
- bioaccess® (sister, Latin America first-in-human CRO): https://www.bioaccessla.com
- Advanced Cardiovascular of Miami (ambulatory surgical center): https://www.advancedcvmiami.com